Results
The demographics of the 88 patients are provided in Table 1. The cohort
had a median age of 64,1±18,2 years. There were 45 (51,1%) men and 43
(48,9%) women. The patients were divided into two groups according to
their mortality as the survival group (group 1) and the non-survive
group (group 2) . Of the 88 patients included in the study, 24 (27%)
died. Ten of the female patients (41.7%) and 14 of the male patients
(58.3%) resulted in death, and there was no significant difference in
mortality between men and women (p= 0.408). Mean age, the non-survive
group was older than the survival group (70 ± 12.3 years vs 61.9 ± 18.2
years, respectively; p= 0.020). With respect to diabetes mellitus,
hypertension, heart disease, chronic obstructive pulmonary disease,
chronic renal failure and other accompanying morbid diseases there was
no significant difference between the two groups (p> 0.05).
27 (42.2%) patients from group 1 have fever while it was present in
only 4 (16.7%) patients from group 2 (p= 0.026). In addition, 23
(35.9%) of the group 1 and 16 (66.7%) of the group 2 had shortness of
breath (p = 0.001). Other symptoms were not significantly different
between both groups (p> 0.05) (Figure 1). Mortality
predictors due to COVID-19 in group 2 patients were significantly higher
than those in group 2 (p <0.05) (Table 2).
The median (IR) value of the MK level was 152.5 pg/ml (125) in all
patients, 143 pg/ml (149) in survivors and 165.5 pg/ml (76) in those who
died. However, the difference between these two groups compared
according to mortality was not statistically significant (p= 0.546)
(Table 1). ROC analysis was performed to determine whether there was a
cut-off value that could be considered significant in predicting
mortality in patients with Covid-19. The area under the ROC curve was
found to be 0.542 (95% Confidence Interval 0.423-0.661, p= 0.546).
Therefore, a suitable cut-off value was not found for statistical
significance (Figure 2).